These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21514150)

  • 41. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.
    Norman MH; Zhu J; Fotsch C; Bo Y; Chen N; Chakrabarti P; Doherty EM; Gavva NR; Nishimura N; Nixey T; Ognyanov VI; Rzasa RM; Stec M; Surapaneni S; Tamir R; Viswanadhan VN; Treanor JJ
    J Med Chem; 2007 Jul; 50(15):3497-514. PubMed ID: 17585749
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of potent, orally bioavailable small-molecule inhibitors of the human CCR2 receptor.
    Doyon J; Coesemans E; Boeckx S; Buntinx M; Hermans B; Van Wauwe JP; Gilissen RA; De Groot AH; Corens D; Van Lommen G
    ChemMedChem; 2008 Apr; 3(4):660-9. PubMed ID: 18188859
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compounds.
    Takeuchi K; Kohn TJ; True TA; Mais DE; Wikel JH; Utterback BG; Wyss VL; Jakubowski JA
    J Med Chem; 1998 Dec; 41(27):5362-74. PubMed ID: 9876106
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
    Poon SF; Eastman BW; Chapman DF; Chung J; Cramer M; Holtz G; Cosford ND; Smith ND
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5477-80. PubMed ID: 15482907
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of novel phenylpyridone derivatives as potent and selective MCH1R antagonists.
    Haga Y; Mizutani S; Naya A; Kishino H; Iwaasa H; Ito M; Ito J; Moriya M; Sato N; Takenaga N; Ishihara A; Tokita S; Kanatani A; Ohtake N
    Bioorg Med Chem; 2011 Jan; 19(2):883-93. PubMed ID: 21190859
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3β inhibitors.
    Coffman K; Brodney M; Cook J; Lanyon L; Pandit J; Sakya S; Schachter J; Tseng-Lovering E; Wessel M
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1429-33. PubMed ID: 21295469
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
    Yang H; Lin XF; Padilla F; Gabriel SD; Heilek G; Ji C; Sankuratri S; deRosier A; Berry P; Rotstein DM
    Bioorg Med Chem Lett; 2009 Jan; 19(1):209-13. PubMed ID: 19014885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Koch S; Rossi KA; Alexander RS; Smallwood A; Wong PC; Rendina AR; Luettgen JM; Knabb RM; He K; Xin B; Wexler RR; Lam PY
    J Med Chem; 2007 Nov; 50(22):5339-56. PubMed ID: 17914785
    [TBL] [Abstract][Full Text] [Related]  

  • 49. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
    Cobb JE; Blanchard SG; Boswell EG; Brown KK; Charifson PS; Cooper JP; Collins JL; Dezube M; Henke BR; Hull-Ryde EA; Lake DH; Lenhard JM; Oliver W; Oplinger J; Pentti M; Parks DJ; Plunket KD; Tong WQ
    J Med Chem; 1998 Dec; 41(25):5055-69. PubMed ID: 9836622
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists.
    He S; Dobbelaar PH; Liu J; Jian T; Sebhat IK; Lin LS; Goodman A; Guo C; Guzzo PR; Hadden M; Henderson AJ; Ruenz M; Sargent BJ; Yet L; Kelly TM; Palyha O; Kan Y; Pan J; Chen H; Marsh DJ; Shearman LP; Strack AM; Metzger JM; Feighner SD; Tan C; Howard AD; Tamvakopoulos C; Peng Q; Guan XM; Reitman ML; Patchett AA; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2010 Mar; 20(6):1913-7. PubMed ID: 20167483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs.
    Zhang P; Bao L; Zuckett JF; Goldman EA; Jia ZJ; Arfsten A; Edwards S; Sinha U; Hutchaleelaha A; Park G; Lambing JL; Hollenbach SJ; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Feb; 14(4):983-7. PubMed ID: 15013006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonists.
    Guo L; Ye Z; Liu J; He S; Bakshi RK; Sebhat IK; Dobbelaar PH; Hong Q; Jian T; Dellureficio JP; Tsou NN; Ball RG; Weinberg DH; MacNeil T; Tang R; Tamvakopoulos C; Peng Q; Chen HY; Chen AS; Martin WJ; MacIntyre DE; Strack AM; Fong TM; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4895-900. PubMed ID: 20621473
    [TBL] [Abstract][Full Text] [Related]  

  • 53. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
    Henke BR; Blanchard SG; Brackeen MF; Brown KK; Cobb JE; Collins JL; Harrington WW; Hashim MA; Hull-Ryde EA; Kaldor I; Kliewer SA; Lake DH; Leesnitzer LM; Lehmann JM; Lenhard JM; Orband-Miller LA; Miller JF; Mook RA; Noble SA; Oliver W; Parks DJ; Plunket KD; Szewczyk JR; Willson TM
    J Med Chem; 1998 Dec; 41(25):5020-36. PubMed ID: 9836620
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potent achiral agonists of the growth hormone secretagogue (ghrelin) receptor. Part 2: Lead optimisation.
    Witherington J; Abberley L; Briggs MA; Collis K; Dean DK; Gaiba A; King NP; Kraus H; Shuker N; Steadman JG; Takle AK; Sanger G; Wadsworth G; Butler S; McKay F; Muir A; Winborn K; Heightman TD
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2203-5. PubMed ID: 18316188
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 2-Amino-9-aryl-3-cyano-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]thieno[2,3-b]pyridine derivatives as selective progesterone receptor agonists.
    Wang Y; Duraiswami C; Madauss KP; Tran TB; Williams SP; Deng SJ; Graybill TL; Hammond M; Jones DG; Grygielko ET; Bray JD; Thompson SK
    Bioorg Med Chem Lett; 2009 Sep; 19(17):4916-9. PubMed ID: 19664922
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor.
    Ando M; Sato N; Nagase T; Nagai K; Ishikawa S; Takahashi H; Ohtake N; Ito J; Hirayama M; Mitobe Y; Iwaasa H; Gomori A; Matsushita H; Tadano K; Fujino N; Tanaka S; Ohe T; Ishihara A; Kanatani A; Fukami T
    Bioorg Med Chem; 2009 Aug; 17(16):6106-22. PubMed ID: 19616955
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.
    Corte JR; Fang T; Pinto DJ; Han W; Hu Z; Jiang XJ; Li YL; Gauuan JF; Hadden M; Orton D; Rendina AR; Luettgen JM; Wong PC; He K; Morin PE; Chang CH; Cheney DL; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2008 May; 18(9):2845-9. PubMed ID: 18424044
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonists.
    Guay D; Beaulieu C; Belley M; Crane SN; DeLuca J; Gareau Y; Hamel M; Henault M; Hyjazie H; Kargman S; Chan CC; Xu L; Gordon R; Li L; Mamane Y; Morin N; Mancini J; Thérien M; Tranmer G; Truong VL; Wang Z; Black WC
    Bioorg Med Chem Lett; 2011 May; 21(10):2832-5. PubMed ID: 21507642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors.
    Jia ZJ; Wu Y; Huang W; Zhang P; Song Y; Woolfrey J; Sinha U; Arfsten AE; Edwards ST; Hutchaleelaha A; Hollennbach SJ; Lambing JL; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1229-34. PubMed ID: 14980671
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
    Asaki T; Aoki T; Hamamoto T; Sugiyama Y; Ohmachi S; Kuwabara K; Murakami K; Todo M
    Bioorg Med Chem; 2008 Jan; 16(2):981-94. PubMed ID: 17964792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.